US protection ending in 2033: Digestive system
As of the edition of 20 October 2026, 29 drugs have US protection that ends in 2033 in digestive system; 23 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
29 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Alpelisib | Ends 2033 (patent) | Marketed | Novartis | PIK3CA | 1 |
| Amivantamab | Ends 2033 (computed from the first US licence) | Marketed | Johnson & Johnson | EGFR, MET | 1 |
| Avibactam | Ends 2033 (exclusivity) | Marketed | AbbVie | 0 | |
| Binimetinib | Ends 2033 (patent) | Marketed | Pfizer | MAP2K1, MAP2K2 | 6 |
| Capivasertib | Ends 2033 (patent) | Marketed | AstraZeneca | AKT1, AKT2, AKT3 | 3 |
| Cilastatin | Ends 2033 (patent) | Marketed | Merck & Co. | DPEP1 | 1 |
| Cravacitinib | Ends 2033 (patent) | Marketed | Bristol Myers Squibb | TYK2 | 1 |
| Dostarlimab | Ends 2033 (computed from the first US licence) | Marketed | GSK | PDCD1 | 1 |
| Erdafitinib | Ends 2033 (patent) | Marketed | Johnson & Johnson | FGFR1, FGFR2, FGFR3 | 4 |
| Evinacumab | Ends 2033 (computed from the first US licence) | Marketed | Regeneron | ANGPTL3 | 2 |
| Ibrutinib | Ends 2033 (patent) | Marketed | AbbVie | BTK | 2 |
| Idelalisib | Ends 2033 (patent) | Marketed | Gilead Sciences | PIK3CD | 1 |
| Ivosidenib | Ends 2033 (patent) | Marketed | Servier | IDH1 | 0 |
| Lefamulin | Ends 2033 (patent) | Marketed | Hong Kong King Friend Industrial | 0 | |
| Linerixibat | Ends 2033 (exclusivity) | Marketed | Alfasigma | SLC10A2 | 1 |
| Lisocabtagene maraleucel | Ends 2033 (computed from the first US licence) | Marketed | Juno Therapeutics | CD19 | 2 |
| Obeticholic acid | Ends 2033 (patent) | Marketed | Alfasigma | NR1H4 | 1 |
| Omega-3-carboxylic acids | Ends 2033 (patent) | Marketed | AstraZeneca | 0 | |
| Pegcetacoplan | Ends 2033 (patent) | Marketed | Biogen | C3 | 2 |
| Ponatinib | Ends 2033 (patent) | Marketed | Takeda | ABL1 | 1 |
| Relacorilant | Ends 2033 (patent) | Marketed | Corcept Therapeutics | NR3C1 | 1 |
| Resmetirom | Ends 2033 (patent) | Marketed | Madrigal Pharmaceuticals | THRB | 1 |
| Ropeginterferon alfa-2b | Ends 2033 (computed from the first US licence) | Marketed | PharmaEssentia | IFNAR1, IFNAR2 | 0 |
| Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae crm197 | Ends 2033 (reference-product exclusivity) | Marketed | Merck & Co. | 0 | |
| Taletrectinib | Ends 2033 (patent) | Marketed | Nuvation Bio | NTRK1, NTRK2, NTRK3 | 8 |
| Tenapanor | Ends 2033 (patent) | Marketed | Ardelyx | SLC9A3 | 2 |
| Tezepelumab | Ends 2033 (computed from the first US licence) | Marketed | AstraZeneca | TSLP | 1 |
| Tisotumab vedotin | Ends 2033 (computed from the first US licence) | Marketed | Pfizer | F3, TUBB, TUBB1 | 11 |
| Tralokinumab | Ends 2033 (computed from the first US licence) | Marketed | LEO Pharma | IL13 | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2033 in digestive system
In the product23 of these 29 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.